Click here for Dr. Rajesh Shah’s talk on COVID-19 Nosode at GIRI conference (Brazil) on 27th Oct 2020
Click here for Dr. Rajesh Shah’s Webinar: Introducing COVID-19 Nosodes
Dr Rajesh Shah: Research experience
Dr Rajesh Shah has an exceptional strength of having a research base in a clinical environment. His clinic has the R & D division engaged in several research projects. He has worked on many new therapeutic molecules; some of them have been granted Patents (in India, US, Europe, Australia, Africa) while some are patent pending. He is a hardcore researcher + clinician + teacher + promoter of homeopathy. He has been working extensively to examine the therapeutic efficacy and clinical effects of using scientific protocols. Through clinical, scientific, and ethical research, he aims at introducing new medicines which are more potent, effective, and scientifically proven; so that they can be used by doctors all across the world.
He has conducted several Homeopathy Pathogenetic Trials (drug proving) and Clinical Trials projects, which have been approved by the Institutional Ethics committee, which functions as per ICMR guidelines. All research projects were conducted considering the CCRH, ECH, and GCP guidance. His recent research conducted at ICT (Mumbai) proved that certain homeopathic medicines are as effective as conventional pain-killerDiclofenac, in the animal model. He is involved in animal studies, in-vitro and in-vivo studies of homeopathic medicines in collaboration with world-class institutes such as ICT (Institute of Chemical Technology, Mumbai), Haffkine Institute (Mumbai), etc. International standards have been used in conducting homeopathic research. The new drugs have been standardized and have undergone extensive scientific research. The safety of drugs has been established.
Dr Shah has conducted several clinical trials on human models and has proved the efficacy of homeopathic medicines in controlled studies, in tune with the conventional medical protocols. Some of the studies include Clinical trials in HIV, Hepatitis C, pain control, etc.
He has developed a potentization method with standardized, scientific force-parameters.
ISO 9001:2000 certified clinic with research wing:
His clinic Life Force is ISO 9001:2000 certified homeopathic clinics with an attached research wing, one of the first in the world. There is a battery of experts from different scientific fields who are a part of the Scientific Advisory Board guiding Dr Shah in homeopathic research. A small research team, doctors, and support staff assist his research work. The team has given proper training to conduct the work according to established standards. Some of the projects are conducted in collaboration with other reputed institutes.
Research projects
i. Preparation of HIV nosode (May-2010)
A new HIV nosode sourced from HIV positive (type I and II negative for other co-infections) was scientifically prepared. The ethics committee, which is constituted and functions as per ICMR guidelines approved the project. The source material, fifteen-step preparation process, and the standardization with respect to viral count, protein profile, pH, and the process of potentization were documented. The HIV nosode in 30c and 50c potencies was prepared. Safety and efficacy were established through clinical trial and homeopathic pathogenetic trials (Drug proving).
ii. Homeopathic Pathogenetic Trial of HIV nosode (June-2011)
Double-blind, randomized placebo-controlled homeopathic pathogenetic trial (drug proving) of HIV nosode, 30c potency was conducted using accepted guidelines, ethical approval, and scientific documentation; with the aim to introduce a new nosode in the homeopathic pharmacopeia. Usable symptoms derived from the study.
iii. HIV nosode clinical trial (May-2010)
An open-label exploratory clinical trial in thirty HIV positive individuals was conducted using the HIV nosode in 30c and 50c potencies. The objectives of this study were to evaluate the efficacy of HIV nosode in HIV-infected participants in terms of reduction in viral load and improvement of the immunological parameter such as CD4 and CD8 count and CD4 percentage and general health parameters.
iv. Preparation of HCV nosode (May-2010)
HCV nosode from sera of HCV type I and III positive (negative for other co-infections) consented donors were prepared by serial dilution and potentization method described in Homeopathic Pharmacopeia. The source material and the preparation process were standardized. The HCV nosode in 30c and 50c potencies was prepared. Safety and efficacy were established through clinical trial and homeopathic pathogenetic trials (Drug proving).
v. HCV nosode clinical trial (May-2010)
An open-label exploratory clinical trial in twenty-six HCV positive individuals was conducted using the HCV nosode in 30c and 50c potencies. The main objective of this study was to evaluate the efficacy of HCV nosode by observing the reduction in viral load from baseline and general health parameters.
vi. Homeopathic Pathogenetic Trial of HCV nosode (June-2011)
Double-blind, randomized placebo-controlled homeopathic pathogenetic trial (drug proving) of HCV nosode, 30c potency was conducted using accepted guidelines, ethical approval, and scientific documentation; with the aim to introduce a new nosode in the homeopathic pharmacopeia. Usable symptoms derived from the study.
vii. Homeopathic Pathogenetic Trial of CP-010 (Jan- 2012)
A double-blind, randomized, placebo-controlled homeopathic pathogenetic trial (HPT/ drug proving) of CP-010 was conducted, using the accepted guidelines, ethical approval, and scientific documentation.
viii. CP-010 clinical trial for pain management (Nov-2011)
A double-blind, randomized, comparative study to evaluate efficacy and safety of CP- 010 with Magnesium phosphoricum was conducted. 116 patients having sub-acute and chronic painful conditions were randomized in the study.
The primary objective of this study was to evaluate the efficacy of potentized preparation CP-30c potency by measuring the reduction in the intensity of pain using the Numeric rating scale (NRS).
ix. Homeopathic Pathogenetic Trial of H-009 (Jan- 2012)
A double-blind, randomized, placebo-controlled homeopathic pathogenetic trial (HPT/ drug proving) of Hydroquinone was conducted, using the accepted guidelines, ethical approval, and scientific documentation; with the aim of introducing a new medicine in the homeopathic pharmacopeia.
x. Preclinical study (animal- Wistar rats) to evaluate the efficacy of CP 010 in arthritis (Oct- 2012)
The anti-arthritic activity of CP 010, Magnesium Phosphoricum were studied in 60 Albino Wistar rats in 6 different groups using a positive and negative control to observes the effect of homeopathy medicines on the animal model. The study proved that homeopathic medicines are as effective as anti-inflammatory Diclofenac on certain days.
xi. Preparation, Standardization and in vitro safety testing of Mycobacterium Nosodes (Emtact- Polyvalent Nosode) (Jan- 2013)
Polyvalent Mycobacterium nosode (Emtact) prepared and standardized using different Mycobacterium strains. Bacterial characteristics, strains, and quantity used, and the process of preparation was documented so that the nosodes can be re-visited, re-developed with scientific validation and standardization. In vivo studies and sterility testing of the nosode were carried out.
xii. A method for preparation of Nosode developed:
The old method of nosode preparation required revamping in the light of the latest development in the areas of microbiology. A scientific, standardized 15-step method was developed for making reproducible nosodes now and in the future.
xiii. Several ongoing research projects in collaboration with reputed institutions.